• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

直接观察治疗策略加强化治疗前耐多药结核病的临床特征及治疗结果:项目经验教训

Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program.

作者信息

Dholakia Yatin N, Shah Divya P

机构信息

The Maharashtra State Anti TB Association, Larsen and Toubro Ltd, Mumbai, India.

出版信息

Lung India. 2013 Oct;30(4):316-20. doi: 10.4103/0970-2113.120608.

DOI:10.4103/0970-2113.120608
PMID:24339490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3841689/
Abstract

BACKGROUND

Characteristics and treatment outcomes of patients with drug-resistant tuberculosis (DR TB) before introduction of directly observed treatment strategy (DOTS) plus are infrequently reported.

AIMS

To study clinical characteristics and treatment outcomes of drug-resistant TB patients.

SETTING

A TB unit in Mumbai.

MATERIALS AND METHODS

A retrospective analysis of DR TB patients attending a TB unit and taking treatment at NGOs was performed. Of the 34 cases, 5 (14%) had mycobacterium other than tuberculosis, 24 were pulmonary TB, 4 extra-pulmonary TB, and one both. Three were HIV-infected, two had diabetes. Two cases were treatment naive. Of the 29 cases studied, 3 (11%) were mono-resistant, 20 (69%) were multidrug-resistant (MDR) TB with E/Z/EZ resistance; 4 were pure MDR TB. One case had XDR TB, 13 (44.8%) had resistance to at least one conventional second-line drug. Seven cases had adverse drug reaction, four requiring drug substitution. Two patients are on treatment; 14 of the remaining 27 (51%) were successfully treated, 5 (18%) died, 2 (7%) failed treatment, 5 (18%) were lost to follow-up, one migrated.

CONCLUSION

DST profiles suggest high levels of drug resistance due to amplification which leads to poor outcomes. There is an urgent need for Indian Revised National TB Control Program to introduce daily DOTS for susceptible cases, DST for all new cases, and scaling up DST for second-line drugs. There is also a need to use individualized treatment for DR TB.

摘要

背景

在直接观察治疗策略(DOTS)加强化治疗引入之前,耐多药结核病(DR TB)患者的特征及治疗结果鲜有报道。

目的

研究耐多药结核病患者的临床特征及治疗结果。

地点

孟买的一个结核病治疗单位。

材料与方法

对在一个结核病治疗单位就诊并在非政府组织接受治疗的耐多药结核病患者进行回顾性分析。34例患者中,5例(14%)感染的是非结核分枝杆菌,24例为肺结核,4例为肺外结核,1例两者皆有。3例感染了艾滋病毒,2例患有糖尿病。2例为初治患者。在研究的29例患者中,3例(~11%)为单耐药,20例(69%)为耐多药(MDR)结核病,伴有乙胺丁醇/吡嗪酰胺/乙胺丁醇加吡嗪酰胺耐药;4例为单纯耐多药结核病。1例为广泛耐药结核病,13例(44.8%)对至少一种传统二线药物耐药。7例出现药物不良反应,4例需要更换药物。2例患者仍在治疗中;其余27例中的14例(51%)成功治愈,5例(18%)死亡,2例(7%)治疗失败,5例(1~8%)失访,1例移居国外。

结论

药物敏感性试验结果表明,由于扩增导致的高耐药水平会导致不良后果。印度修订的国家结核病控制规划迫切需要对易感病例采用每日直接观察治疗,对所有新病例进行药物敏感性试验,并扩大二线药物的药物敏感性试验。还需要对耐多药结核病采用个体化治疗。

相似文献

1
Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program.直接观察治疗策略加强化治疗前耐多药结核病的临床特征及治疗结果:项目经验教训
Lung India. 2013 Oct;30(4):316-20. doi: 10.4103/0970-2113.120608.
2
Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory.白俄罗斯结核病合并艾滋病病毒阳性患者的结核病药物敏感性、治疗及转归:一项国家和国际实验室的研究结果
Tuberc Res Treat. 2021 Apr 2;2021:6646239. doi: 10.1155/2021/6646239. eCollection 2021.
3
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.《2006年抗结核药物国际共识指南:肺结核、肺外结核及特殊情况结核病的管理》
J Assoc Physicians India. 2006 Mar;54:219-34.
4
Tuberculosis结核病
5
Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.修订后的 II 类方案可作为 I 类方案失败和不规则治疗病例再治疗的替代策略。
Am J Ther. 2011 Sep;18(5):343-9. doi: 10.1097/MJT.0b013e3181dd60ec.
6
Changing prevalence and resistance patterns in children with drug-resistant tuberculosis in Mumbai.孟买耐药性肺结核患儿中不断变化的患病率和耐药模式。
Paediatr Int Child Health. 2017 May;37(2):135-138. doi: 10.1080/20469047.2016.1214796. Epub 2016 Aug 9.
7
Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011.2011年越南耐多药结核病患者对二线抗结核药物的耐药率
Western Pac Surveill Response J. 2016 Jun 8;7(2):35-40. doi: 10.5365/WPSAR.2016.7.2.002. eCollection 2016 Apr-Jun.
8
Extrapulmonary drug-resistant tuberculosis at a drug-resistant tuberculosis center, Mumbai: Our experience - Hope in the midst of despair!孟买一家耐药结核病中心的肺外耐药结核病:我们的经验——绝望中的希望!
Lung India. 2019 Jan-Feb;36(1):3-7. doi: 10.4103/lungindia.lungindia_192_18.
9
Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community.高 HIV 流行地区耐多药和广泛耐药结核病的预测因素。
PLoS One. 2010 Dec 29;5(12):e15735. doi: 10.1371/journal.pone.0015735.
10
Drug resistance characteristics of Mycobacterium tuberculosis isolates between 2014 and 2017 in Sichuan, China: A retrospective study.2014 年至 2017 年中国四川结核分枝杆菌分离株的耐药特征:一项回顾性研究。
PLoS One. 2018 Dec 31;13(12):e0209902. doi: 10.1371/journal.pone.0209902. eCollection 2018.

引用本文的文献

1
Prevalence of pre-extensively drug-resistant tuberculosis (Pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among extra pulmonary (EP) multidrug resistant tuberculosis (MDR-TB) at a tertiary care center in Mumbai in pre Bedaquiline (BDQ) era.在孟买一家三级医疗中心,在使用贝达喹啉(BDQ)之前的时代,肺外(EP)耐多药结核病(MDR-TB)中广泛耐药前结核病(Pre XDR-TB)和广泛耐药结核病(XDR-TB)的患病率。
Lung India. 2023 Jan-Feb;40(1):19-23. doi: 10.4103/lungindia.lungindia_182_22.
2
Determinants of multidrug-resistant tuberculosis in São Paulo-Brazil: a multilevel Bayesian analysis of factors associated with individual, community and access to health services.巴西圣保罗地区耐多药结核病的决定因素:个体、社区和获得卫生服务相关因素的多层次贝叶斯分析。
Trop Med Int Health. 2020 Jul;25(7):839-849. doi: 10.1111/tmi.13409. Epub 2020 May 28.
3
Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: A 2 years' experience.采用改良强化间歇短程化疗策略治疗耐多药结核病的疗效:两年经验
Lung India. 2019 Sep-Oct;36(5):384-392. doi: 10.4103/lungindia.lungindia_475_18.
4
Antigen 85B peptidomic analysis allows species-specific mycobacterial identification.抗原85B肽组学分析可实现分枝杆菌的种特异性鉴定。
Clin Proteomics. 2018 Jan 8;15:1. doi: 10.1186/s12014-017-9177-6. eCollection 2018.
5
Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.印度广泛耐药结核病:关于诊断与管理的当前证据
Indian J Med Res. 2017 Mar;145(3):271-293. doi: 10.4103/ijmr.IJMR_177_16.
6
Tuberculosis therapy in Mumbai: Critical importance of drug-susceptibility testing.孟买的结核病治疗:药敏试验的至关重要性。
Lung India. 2016 May-Jun;33(3):251-2. doi: 10.4103/0970-2113.180799.
7
Prevalence of Multidrug Resistant Pulmonary Tuberculosis in North Bihar.北比哈尔邦耐多药肺结核的患病率
J Clin Diagn Res. 2015 Nov;9(11):LC09-12. doi: 10.7860/JCDR/2015/14024.6793. Epub 2015 Nov 1.
8
Issues in the management of drug resistant tuberculosis in India.印度耐多药结核病管理中的问题
Lung India. 2013 Oct;30(4):269-72. doi: 10.4103/0970-2113.120592.

本文引用的文献

1
DOT, S, or DOTS?直接观察治疗、短程化疗,还是全程督导短程化疗?
Public Health Action. 2012 Mar 21;2(1):3-4. doi: 10.5588/pha.12.0007.
2
Chest X-rays and associated clinical parameters in pulmonary tuberculosis cases from the National Tuberculosis Programme, Mumbai.来自孟买国家结核病防治项目的肺结核病例的胸部X光片及相关临床参数。
Infect Dis Rep. 2012 Jan 18;4(1):e10. doi: 10.4081/idr.2012.e10. eCollection 2012 Jan 2.
3
Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough.二线耐药对美国结核病治疗结局的影响:耐多药结核病已经够糟糕了。
Int J Tuberc Lung Dis. 2012 Oct;16(10):1331-4. doi: 10.5588/ijtld.11.0812. Epub 2012 Aug 3.
4
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India.在印度孟买,接受抗逆转录病毒和二线抗结核治疗的 HIV/MDR-TB 合并感染患者的不良事件。
PLoS One. 2012;7(7):e40781. doi: 10.1371/journal.pone.0040781. Epub 2012 Jul 11.
5
Totally drug-resistant tuberculosis in India: who let the djinn out?印度的完全耐药结核病:究竟是谁放出了这头“恶魔”?
Respirology. 2012 Jul;17(5):741-2. doi: 10.1111/j.1440-1843.2012.02192.x.
6
Ethics, human rights and programmatic management of drug-resistant tuberculosis.耐药结核病的伦理学、人权与项目管理
Lung India. 2012 Jan;29(1):95-6. doi: 10.4103/0970-2113.92384.
7
Totally drug-resistant tuberculosis in India.印度的完全耐药结核病
Clin Infect Dis. 2012 Feb 15;54(4):579-81. doi: 10.1093/cid/cir889. Epub 2011 Dec 21.
8
Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India.印度孟买贫民窟中感染 HIV 的患者队列中,门诊耐多药结核病治疗结局。
PLoS One. 2011;6(12):e28066. doi: 10.1371/journal.pone.0028066. Epub 2011 Dec 1.
9
Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India.印度安得拉邦诊断耐多药结核病和启动治疗方面的操作挑战。
PLoS One. 2011;6(11):e26659. doi: 10.1371/journal.pone.0026659. Epub 2011 Nov 2.
10
Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment.耐多药结核病治疗的微生物监测频率和类型。
Int J Tuberc Lung Dis. 2011 Nov;15(11):1553-5, i. doi: 10.5588/ijtld.11.0101.